The clinical diagnosis of amiodarone-induced pulmonary toxicity (APT) requires two or more of the following criteria:
- new onset of pulmonary symptoms such as dyspnea, cough, or pleuritic chest pain;
- new chest radiographic abnormality such as an interstitial or alveolar infiltrate;
- a decrease in the DLCO of 20% from the pretreatment value, or if none is available, a value less than 80% of predicted;
- abnormal lung uptake with gallium-67 radioisotope; and
- characteristic histologic changes of lung tissue obtained by bronchoscopic or open lung biopsy.